Background: Antimicrobial resistance (AMR) thwarts the curative power of drugs and is a present-time global problem. We present data on antimicrobial susceptibility and resistance determinants of bacteria the WHO has highlighted as being key antimicrobial resistance concerns in Africa, to strengthen knowledge of AMR patterns in the region.
Methods: Blood, stool, and urine specimens of febrile patients, aged between ≥ 30 days and ≤ 15 years and hospitalized in Burkina Faso, Gabon, Ghana, and Tanzania were cultured from November 2013 to March 2017 (Patients > 15 years were included in Tanzania). Antimicrobial susceptibility testing was performed for all Enterobacterales and isolates using disk diffusion method. Extended-spectrum beta-lactamase (ESBL) production was confirmed by double-disk diffusion test and the detection of , and . Multilocus sequence typing was conducted for ESBL-producing and , ciprofloxacin-resistant and . Ciprofloxacin-resistant were screened for plasmid-mediated resistance genes and mutations in . isolates were tested for the presence of and Panton-Valentine Leukocidin and further genotyped by typing.
Results: Among 4,052 specimens from 3,012 patients, 219 cultures were positive of which 88.1% ( = 193) were Enterobacterales and 7.3% ( = 16) . The prevalence of ESBL-producing Enterobacterales (all CTX-M15 genotype) was 45.2% (14/31; 95% CI: 27.3, 64.0) in Burkina Faso, 25.8% (8/31; 95% CI: 11.9, 44.6) in Gabon, 15.1% (18/119; 95% CI: 9.2, 22.8) in Ghana and 0.0% (0/12; 95% CI: 0.0, 26.5) in Tanzania. ESBL positive non-typhoid ( = 3) were detected in Burkina Faso only and methicillin-resistant ( = 2) were detected in Ghana only. While sequence type (ST)131 predominated among ESBL (39.1%;9/23), STs among ESBL were highly heterogenous. Ciprofloxacin resistant nt were commonest in Burkina Faso (50.0%; 6/12) and all harbored genes. were found in 81.3% .
Conclusion: Our findings reveal a distinct susceptibility pattern across the various study regions in Africa, with notably high rates of ESBL-producing Enterobacterales and ciprofloxacin-resistant nt in Burkina Faso. This highlights the need for local AMR surveillance and reporting of resistances to support appropriate action.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546812 | PMC |
http://dx.doi.org/10.3389/fmicb.2020.567235 | DOI Listing |
Vaccines (Basel)
January 2025
Leiden University Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Background: Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well as a major contributor to gut enteropathy and stunting. There are currently no licensed vaccines for shigellosis but it has been estimated that an effective vaccine could avert 590,000 deaths over a 20-year period. A challenge to effective Shigella vaccine development has been the low immunogenicity and protective efficacy of candidate Shigella vaccines in infants and young children.
View Article and Find Full Text PDFTrop Med Infect Dis
December 2024
National Institute of Public Health, Abidjan BP V 47, Côte d'Ivoire.
Seasonal malaria chemoprevention (SMC) is a strategy recommended by the World Health Organization for children aged 3-59 months in the Sahel and sub-Sahel regions where malaria transmission is seasonal. In Côte d'Ivoire, malaria remains a high priority and accounts for the majority of consultations and deaths in children under five. The recent revision of the criteria for the introduction of seasonal malaria chemoprevention has made the north of Côte d'Ivoire, where malaria transmission is seasonal, eligible for the SMC.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Clinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Ouagdougou, 11 BP218, Burkina Faso.
Background: Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE), particularly Escherichia coli and Klebsiella pneumoniae, have been consistently associated with treatment failure, high mortality and morbidity. The emergence of carbapenem resistance among ESBL-PE strains exacerbates the antimicrobial resistance. However, data are very limited in developing countries as Burkina Faso.
View Article and Find Full Text PDFLancet Infect Dis
January 2025
WHO, Conakry, Guinea.
IJID Reg
March 2025
Department of Public Health, RTU/HS, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Objectives: Less than 25% of people living with HIV (PLWHIV) achieved plasma viral load (PVL) in 2020 in Burkina Faso. This study aimed to identify factors associated with access to PVL in Ouagadougou and Bobo-Dioulasso.
Methods: A cross-sectional analytical study was conducted among PLWHIV in Burkina Faso between April 15 and August 8, 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!